Impact of MLL5 expression on decitabine efficacy and DNA methylation in acute myeloid leukemia
Haematologica, 2014 Hypomethylating agents are widely used in patients with myelodysplastic syndromes and unfit patients with acute myeloid leukemia. However, it is not well understood why only some patients respond to hypomethylating agents.
Haiyang Yun +13 more
doaj +1 more source
npj Breast Cancer, 2023 TROP2 antibody drug conjugates (ADCs) are under active development. We seek to determine whether we can enhance activity of TROP2 ADCs by increasing TROP2 expression.
Ming Zhao +12 more
doaj +1 more source
Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. [PDF]
, 2019 Optimization of post-remission therapies to maintain complete remission and prevent relapse is a major challenge in treating patients with acute myeloid leukemia (AML).
Chan, Steven M +4 more
core +1 more source
The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemia
Therapeutic Advances in Hematology, 2023 Decitabine, a member of the 5-azanucleosides, has a dose-dependent mechanism of action in vitro : termination of DNA replication at high doses, and inhibition of DNA methyltransferase at low doses.
Robert Briski +3 more
doaj +1 more source
DNMT inhibitors reverse a specific signature of aberrant promoter DNA methylation and associated gene silencing in AML [PDF]
, 2014 <b>Background</b>. Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) are neoplastic disorders of hematopoietic stem cells. DNA methyltransferase inhibitors (DNMTi), 5-azacytidine (AzaC) and 5-aza-2’-deoxycytidine (Decitabine),
Adams, Peter +8 more
core +2 more sources
Epigenetic and antitumor effects of platinum(IV)-octanoato conjugates [PDF]
, 2017 We present the anticancer properties of cis, cis, trans-[Pt(IV)(NH3)2Cl2(OA)2] [Pt(IV)diOA] (OA = octanoato), Pt(IV) derivative of cisplatin containing two OA units appended to the axial positions of a six-coordinate Pt(IV) center.
Brabec, Viktor +8 more
core +1 more source
Tumor-reactive immune cells protect against metastatic tumor and induce immunoediting of indolent but not quiescent tumor cells [PDF]
, 2016 Two major barriers to cancer immunotherapy include tumor-induced immune suppression mediated by myeloid-derived suppressor cells and poor immunogenicity of the tumor-expressing self-antigens.
Bear, Harry D. +8 more
core +2 more sources
Journal of International Medical Research, 2022 Objective Combination therapy has become the hallmark of lung cancer treatment, as it reduces the dosage intensity of individual drugs while increasing their efficacy.
Maoyi Xu +3 more
doaj +1 more source
Epigenetic treatment of solid tumours. A review of clinical trials [PDF]
, 2015 Epigenetic treatment has been approved by regulatory agencies for haematological malignancies. The success observe in cutaneous lymphomas represents a proof of principle that similar results may be obtained in solid tumours. Several agents that interfere
CODACCI PISANELLI, Giovanni +2 more
core +2 more sources
Decitabine, a DNA-demethylating agent, promotes differentiation via NOTCH1 signaling and alters immune-related pathways in muscle-invasive bladder cancer [PDF]
, 2017 Aberrant DNA methylation observed in cancer can provide survival benefits to cells by silencing genes essential for anti-tumor activity. DNA-demethylating agents such as Decitabine (DAC)/Azacitidine (AZA) activate otherwise silenced tumor suppressor ...
Attwood, Kristopher +16 more
core +3 more sources